{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:41:46Z","timestamp":1790743306424,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40262-017-0550-4","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T02:39:52Z","timestamp":1494815992000},"page":"71-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Ping","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adimoolam","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Olsson","family":"Gisleskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Melhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,15]]},"reference":[{"issue":"Suppl 3","key":"550_CR1","first-page":"S241","volume":"21","author":"SM Moe","year":"2001","unstructured":"Moe SM. Current issues in the management of secondary hyperparathyroidism and bone disease. Perit Dial Int. 2001;21(Suppl 3):S241\u20136.","journal-title":"Perit Dial Int"},{"key":"550_CR2","unstructured":"US Renal Data System. Atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009."},{"issue":"2","key":"550_CR3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00000441-200008000-00008","volume":"320","author":"C Diaz-Corte","year":"2000","unstructured":"Diaz-Corte C, Cannata-Andia JB. Management of secondary hyperparathyroidism: the gap between diagnosis and treatment. The Renal Osteodystrophy Multicenter Enquiry. Am J Med Sci. 2000;320(2):107\u201311.","journal-title":"Am J Med Sci"},{"issue":"5","key":"550_CR4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0272-6386(97)90484-4","volume":"30","author":"S Bro","year":"1997","unstructured":"Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis. 1997;30(5):606\u201320.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"550_CR5","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0272-6386(00)70064-3","volume":"35","author":"GA Block","year":"2000","unstructured":"Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000;35(6):1226\u201337.","journal-title":"Am J Kidney Dis"},{"key":"550_CR6","doi-asserted-by":"crossref","unstructured":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1\u2013201.","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"550_CR7","unstructured":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1\u2013130."},{"issue":"5","key":"550_CR8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3122\/jabfm.2009.05.090026","volume":"22","author":"W Saliba","year":"2009","unstructured":"Saliba W, El-Haddad B. Secondary hyperparathyroidism: pathophysiology and treatment. J Am Board Fam Med. 2009;22(5):574\u201381.","journal-title":"J Am Board Fam Med"},{"issue":"4","key":"550_CR9","first-page":"363","volume":"9","author":"F Locatelli","year":"2008","unstructured":"Locatelli F, Limardo M, Pontoriero G. New approaches to treatment of secondary hyperparathyroidism. Curr Opin Investig Drugs. 2008;9(4):363\u201370.","journal-title":"Curr Opin Investig Drugs"},{"issue":"6","key":"550_CR10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jcph.460","volume":"55","author":"P Chen","year":"2015","unstructured":"Chen P, Melhem M, Xiao J, Kuchimanchi M, Perez Ruixo JJ. Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol. 2015;55(6):620\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"550_CR11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/psp4.12106","volume":"5","author":"P Chen","year":"2016","unstructured":"Chen P, Olsson Gisleskog P, Perez-Ruixo JJ, Xiao J, Wilkins J, Narayanan A, et al. Population pharmacokinetics and pharmacodynamics of the calcimimetic etelcalcetide in chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis. CPT Pharmacomet Syst Pharmacol. 2016;5(9):484\u201394.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"5","key":"550_CR12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000442754","volume":"42","author":"DA Bushinsky","year":"2015","unstructured":"Bushinsky DA, Block GA, Martin KJ, Bell G, Huang S, Sun Y, et al. Treatment of secondary hyperparathyroidism: results of a phase 2 trial evaluating an intravenous peptide agonist of the calcium-sensing receptor. Am J Nephrol. 2015;42(5):379\u201388.","journal-title":"Am J Nephrol"},{"issue":"6","key":"550_CR13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","volume":"30","author":"L Zhang","year":"2003","unstructured":"Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30(6):387\u2013404.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"550_CR14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1357-2725(00)00031-5","volume":"32","author":"N Chattopadhyay","year":"2000","unstructured":"Chattopadhyay N. Biochemistry, physiology and pathophysiology of the extracellular calcium-sensing receptor. Int J Biochem Cell Biol. 2000;32(8):789\u2013804.","journal-title":"Int J Biochem Cell Biol"},{"issue":"9","key":"550_CR15","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463\u20138.","journal-title":"Pharm Res"},{"key":"550_CR16","unstructured":"Bauer RJ. NONMEM users guide: introduction to NONMEM 7.2.0. 2011. Available at: https:\/\/nonmem.iconplc.com\/nonmem720\/readme_720.txt ."},{"issue":"8","key":"550_CR17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/j.1552-4604.1995.tb04117.x","volume":"35","author":"H Boxenbaum","year":"1995","unstructured":"Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol. 1995;35(8):763\u20136.","journal-title":"J Clin Pharmacol"},{"key":"550_CR18","doi-asserted-by":"crossref","unstructured":"Shrestha RP. A mathematical model of acute response of parathyroid hormone to changes in plasma ionized calcium in normal humans. University of Massachusetts; 2008. Available at: http:\/\/scholarworks.umass.edu\/theses\/118 .","DOI":"10.1115\/IMECE2008-67551"},{"issue":"1 Suppl","key":"550_CR19","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1177\/0091270011412967","volume":"52","author":"MM Riggs","year":"2012","unstructured":"Riggs MM, Peterson MC, Gastonguay MR. Multiscale physiology-based modeling of mineral bone disorder in patients with impaired kidney function. J Clin Pharmacol. 2012;52(1 Suppl):45S\u201353S.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"550_CR20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bone.2009.08.053","volume":"46","author":"MC Peterson","year":"2010","unstructured":"Peterson MC, Riggs MM. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone. 2010;46(1):49\u201363.","journal-title":"Bone"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-017-0550-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0550-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0550-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T16:47:46Z","timestamp":1569343666000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-017-0550-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["550"],"URL":"https:\/\/doi.org\/10.1007\/s40262-017-0550-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,15]]}}}